Cyclacel Pharmaceuticals, Inc. (CYCC): Price and Financial Metrics

Cyclacel Pharmaceuticals, Inc. (CYCC): $0.37

0.00 (-0.62%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add CYCC to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#169 of 338

in industry

CYCC Price/Volume Stats

Current price $0.37 52-week high $6.00
Prev. close $0.37 52-week low $0.34
Day low $0.36 Volume 290,800
Day high $0.39 Avg. volume 707,430
50-day MA $0.80 Dividend yield N/A
200-day MA $1.64 Market Cap 798.67K

CYCC Stock Price Chart Interactive Chart >


Cyclacel Pharmaceuticals, Inc. (CYCC) Company Bio


Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.


CYCC Latest News Stream


Event/Time News Detail
Loading, please wait...

CYCC Latest Social Stream


Loading social stream, please wait...

View Full CYCC Social Stream

CYCC Price Returns

1-mo -74.13%
3-mo -69.67%
6-mo -81.95%
1-year -91.18%
3-year -99.37%
5-year -99.76%
YTD -86.14%
2023 -73.31%
2022 -82.85%
2021 -50.19%
2020 -41.72%
2019 10.74%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!